Advertisement

hautnah

pp 1–6 | Cite as

Aktuelle Therapie der systemischen Sklerodermie

  • Nicolas HunzelmannEmail author
Bindegewebserkrankung
  • 18 Downloads

Zusammenfassung

Die systemische Sklerose (SSc, Sklerodermie) ist eine schwere chronisch entzündliche Bindegewebserkrankung der Haut, des muskuloskeletalen Systems und vieler innerer Organe. Der heterogene, langjährige Verlauf dieser Erkrankung mit dem Befall multipler Organe stellt eine besondere Herausforderung an den betreuenden Arzt dar. Die therapeutischen Möglichkeiten haben sich in den vergangenen Jahren in verschiedenen Bereichen entscheidend verbessert. Diese positiven Entwicklungen haben dazu geführt, dass in verschiedenen Arbeitsgruppen abgestimmte Empfehlungen zur Behandlung der SSc veröffentlicht wurden. Ziel dieser Übersicht ist es, die wesentlichen Empfehlungen vorzustellen und in ein Konzept einer modernen interdisziplinären Betreuung einzubetten.

Schlüsselwörter

Systemische Sklerose Organbeteiligung Pharmakologische Therapie Fibrose Bindegewebserkrankung  

Current treatment of systemic scleroderma

Abstract

Systemic sclerosis (scleroderma) is a severe, chronic inflammatory connective tissue disease involving the skin, musculoskeletal system, and several internal organs. The heterogeneity of its presentation and course are a particular challenge for the treating physician. As therapeutic options have improved considerably during recent years, various working groups have published consensus recommendations for the treatment of SSc. The aim of this overview is to present major aspects of these recommendations and embed them in a concept of modern interdisciplinary care for this often still devastating disease.

Keywords

Systemic sclerosis Organ involvement Pharmacological therapy Fibrosis Connective tissue diseases 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

N. Hunzelmann gibt Interessenkonflikte durch Vortragshonorare von Actelion, Bayer, Boehringer, Pfizer, Roche an.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54(9):845–851CrossRefGoogle Scholar
  2. 2.
    Belz D, Hunzelmann N, Moinzadeh P (2014) Digital ulcers in scleroderma. Hautarzt 65(11):944–948CrossRefGoogle Scholar
  3. 3.
    Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40:1038–1043CrossRefGoogle Scholar
  4. 4.
    Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, Fligelstone K, Gompels LL, Griffiths B, Herrick AL, Pang J, Parker L, Redmond A, van Laar J, Warburton L, Ong VH (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55(10):1906–1910CrossRefGoogle Scholar
  5. 5.
    Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O (2016) EUSTAR coauthors.A Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis 75(10):1743–1748CrossRefGoogle Scholar
  6. 6.
    Elhai M, Meunier M, Matucci-Cerinic M et al (2013) EUSTAR (EULAR Scleroderma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72(7):1217–1220CrossRefGoogle Scholar
  7. 7.
    Hansi N, Thoua N, Carulli M, Chakravarty K, Lal S et al (2014) Consensus best practice pathway of the UK Scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 32(Suppl 86):214–221Google Scholar
  8. 8.
    Herrick AL (2012) The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 8:469–479CrossRefGoogle Scholar
  9. 9.
    Hoffmann-Vold AM, Aaløkken TM, Lund MB, Garen T, Midtvedt Ø, Brunborg C, Gran JT, Molberg Ø (2015) Predictive value of serial HRCT analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 67:2205–2212CrossRefGoogle Scholar
  10. 10.
    van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35(4):364–372CrossRefGoogle Scholar
  11. 11.
    Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B et al (2015) Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology 54:2015–2024CrossRefGoogle Scholar
  12. 12.
    Hunzelmann N, Genth E, Krieg T et al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47:1185–1192CrossRefGoogle Scholar
  13. 13.
    Knobler R, Moinzadeh P, Hunzelmann N et al (2017) European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 31:1401–1424CrossRefGoogle Scholar
  14. 14.
    Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I et al (2017) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–628CrossRefGoogle Scholar
  15. 15.
    Kreuter A, Breuckmann F, Uhle A, Brockmeyer N, von Kobyletzki G et al (2004) Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 50:740–747CrossRefGoogle Scholar
  16. 16.
    Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I et al (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. Lancet Respir Med 1:369–376CrossRefGoogle Scholar
  17. 17.
    Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–38CrossRefGoogle Scholar
  18. 18.
    Mihai C, Landewé R, van der Haijde D, Walker UA, Constantin PI et al (2015) Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 75:681–686CrossRefGoogle Scholar
  19. 19.
    Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L (2014) Scleroderma renal crisis. J Rheumatol 41:1040–1048CrossRefGoogle Scholar
  20. 20.
    Riemekasten G, Hoffmann U, Sunderkötter C, Weiss N, Kuhn A (2012) angiologisch-dermatologisch-rheumatologische DU-Expertenboard. Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr 137:34–40CrossRefGoogle Scholar
  21. 21.
    Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696–1699CrossRefGoogle Scholar
  22. 22.
    Shreiner AB, Murray C, Denton CP, Khanna D (2016) Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 1(3):247–256.  https://doi.org/10.5301/jsrd.5000214 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G (2013) Scleroderma lung disease. Eur Respir Rev 22:6–19CrossRefGoogle Scholar
  24. 24.
    Steen VD, Medsger TA Jr. (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944CrossRefGoogle Scholar
  25. 25.
    Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA et al (2018) Myeloablative Autologous stem-cell transplantation for severe Scleroderma. N Engl J Med 378:35–47CrossRefGoogle Scholar
  26. 26.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666CrossRefGoogle Scholar
  27. 27.
    Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenylate versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:208CrossRefGoogle Scholar
  28. 28.
    Tingey T, Shu J, Smuczek J, Pope J (2013) Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 65:1460–1471CrossRefGoogle Scholar
  29. 29.
    Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311:2490–2498CrossRefGoogle Scholar
  30. 30.
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr. et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Dermatologie und VenerologieUniklinik KölnKölnDeutschland

Personalised recommendations